A number of small-molecule CDK8/19 inhibitors have been developed [1]; such inhibitors showed in vivo therapeutic effects in leukemia [10,11], lung [8], breast [9], colon [6] and prostate cancers [12]. The gene discussed is CDK8; the disease is leukemia.